阿托伐他汀钙治疗慢性硬膜下血肿的临床疗效及其安全性

目的探讨阿托伐他汀钙治疗慢性硬膜下血肿(CSDH)的临床疗效及其安全性。方法选取新疆生产建设兵团第四师医院2017年11月—2019年11月收治的CSDH患者40例,采用随机数字表法分为对照组和治疗组,各20例。对照组行常规治疗,治疗组在对照组基础上给予阿托伐他汀钙治疗。比较2组治疗前及治疗1周、1个月、3个月后血肿量、Markwalder分级量表(MGS)分级,治疗前、治疗3个月后格拉斯哥评分量表(GCS)评分、日常生活能力(ADL)-BI评分,并比较2组临床疗效、不良反应发生情况。结果治疗前、治疗1周后2组血肿量比较,差异无统计学意义(P>0.05);治疗1个月、3个月后治疗组血肿量少于对照组(P<0.05)。治疗前及治疗1周后、治疗1个月后2组MGS分级比较,差异无统计学意义(P>0.05);治疗3个月后2组MGS分级比较,差异有统计学意义(P<0.05)。治疗前2组GCS评分、ADL-BI评分比较,差异无统计学意义(P>0.05);治疗3个月后治疗组GCS评分、ADL-BI评分高于对照组(P<0.05)。治疗3个月后治疗组总有效率高于对照组(P<0.05)。2组均未见明显不良反应发生。结论阿托伐他汀钙治疗CSDH的临床疗效确切,能够减少血肿量,改善其意识状态、日常生活能力,且安全性较高。

Clinical efficacy and safety of atorvastatin calcium in the treatment of chronic subdural hematoma

Objective To investigate the clinical efficacy and safety of atorvastatin calcium in the treatment of chronic subdural hematoma(CSDH).Methods A total of 40 cases of patients with CSDH were selected from November 2017 to November 2019 in Hospital of the Fourth Division of Xinjiang Production and Construction Corps,which were divided into control group and treatment group according to random number table,20 cases in each group.The control group was given conventional treatment,and the treatment group was given atorvastatin calcium on the basis of the control group.The hematoma volume,Markwalder Rating Scale(MGS)were compared before treatment,1 week,1 month and 3 months after treatment,Glasgow scale(GCS)and activity of daily living(ADL)-BI scores were compared before treatment,3 months after treatment,and the clinical efficacy and adverse reactions were compared between the two groups.Results There was no significant difference in the amount of hematoma between the two groups before and 1 week after treatment(P>0.05);the amount of hematoma in the treatment group was less than that in the control group 1 month and 3 months after treatment(P<0.05).There was no significant difference in MGS classification before treatment,1 week after treatment and 1 month after treatment(P>0.05);there was significant difference in MGS classification between the two groups 3 months after treatment(P<0.05).Before treatment,there was no significant difference in GCS score and ADL-BI score between the two groups(P>0.05);after 3 months of treatment,GCS score and ADL-BI score of the treatment group were higher than those of the control group(P<0.05).After 3 months of treatment,the total effective rate of the treatment group was higher than that of the control group(P<0.05).There was no obvious adverse reaction in both groups.Conclusion Atorvastatin calcium has definite clinical effect in the treatment of CSDH,which can reduce the amount of hematoma,improve the state of consciousness and activities of daily living,and with high safety.